Recent Quotes (30 days)

You have no recent quotes
chg | %

Avivagen Inc  

(Public, CVE:VIV)   Watch this stock  
Find more results for CVE:CFR
0.0000 (0.00%)
Delayed:   1:53PM EDT
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range     -
52 week 0.05 - 0.11
Open     -
Vol / Avg. 0.00/333,227.00
Mkt cap 15.71M
P/E     -
Div/yield     -
EPS -0.01
Shares 196.38M
Beta 0.34
Inst. own     -

Key stats and ratios

Q1 (Jan '15) 2014
Net profit margin -1982.42% -703.62%
Operating margin -1982.42% -703.62%
EBITD margin - -692.42%
Return on average assets -152.44% -183.25%
Return on average equity - -
CDP Score - -


100 Sussex Drive
+1-613-9498164 (Phone)
+1-613-9930796 (Fax)

Website links


Avivagen Inc. is a Canada-based development stage biotechnology company. The Company is focused on bringing products based on its OxC-Beta (oxidized carotenoid) technology, to assist in optimizing health and daily quality of life in companion and feed animals. The Corporation is organized into two operating segments: OxC-Beta and Chemistry service. The Company has created a branded line of companion animal products, Vivamune Health Chews that accesses a direct-to-consumer market, selling primarily via the internet and through specialty pet stores. The Company focuses on its livestock business development efforts on Asian markets due to larger commercial potential and faster approval pathways.

Officers and directors

Cameron Groome President, Chief Executive Officer, Director
Chris Boland Chief Financial Officer
David Hankinson Executive Director
Graham Burton Director - Commercialization Science, Director
David G. P. Allan Director
Vanessa Grant Director
G.F. Kym Anthony Independent Director
Amin I. Khalifa Independent Director